Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States - 18/06/18
, Morgan Birabaharan, BS, Andrew Strunk, MAAbstract |
Background |
Few studies have evaluated the relationship between hidradenitis suppurativa (HS) and type 2 diabetes mellitus (T2DM), and the existing data show conflicting results.
Objective |
To determine the prevalence of T2DM among patients with HS and identify at-risk demographic subgroups.
Methods |
Cross-sectional analysis identifying T2DM among patients with and without HS from a demographically heterogeneous population-based sample of more than 50 million patients in the United States.
Results |
The overall prevalence of T2DM among patients with HS was 24.8% (10,705 of 43,105) compared with 15.6% (1,993,320 of 12,527,570) among patients without HS. The prevalence was highest among patients with HS who were male (3045 of 10,785 [28.2%]), older (1945 of 3950 [49.2%]), nonwhite (4665 of 17,495 [26.7%]), obese (9065 of 30,855 [29.4%]), tobacco smokers (6880 of 25,005 [27.5%]), hypertensive (8595 of 19,610 [43.8%]), and hyperlipidemic (7965 of 17,190 [46.3%]). In univariable and multivariable analyses, patients with HS had 1.75 (95% confidence interval [CI], 1.71-1.79) and 1.58 (95% CI, 1.54-1.62) times the odds, respectively, of having T2DM. HS was associated with T2DM across all demographic subgroups. The association was stronger for younger patients (an OR of 1.67 and 95% CI of 1.60-1.72 for ages 18-44 years vs an OR of 1.50 and 95% CI of 1.41-1.61 for ages ≥65 years).
Limitations |
We lacked information on HS disease severity.
Conclusion |
Patients with HS with risk factors, signs, or symptoms of T2DM should be screened.
Le texte complet de cet article est disponible en PDF.Key words : diabetes mellitus, hidradenitis suppurativa, prevalence, United States
Abbreviations used : BMI, CI, HS, ICD-9, OR, PPV, SNOMED-CT, T2DM, TNF-α
Plan
| Funding sources: Supported in part by an education grant from AbbVie. |
|
| Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, and Asana Biosciences and has received honoraria. Drs Birabaharan and Strunk have no conflicts of interest to disclose. |
|
| The sponsor had no role in design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. |
|
| Reprints not available from the authors. |
Vol 79 - N° 1
P. 71-76 - juillet 2018 Retour au numéro
Article précédent
- Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? : A critical question that we are only just beginning to answer
- Joel M. Gelfand
- Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease
- Basil Patel, Neelam Khan, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?